Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene therapy to ...
The treatment is the first approved gene therapy for AADC deficiency, the FDA said. People with this rare disorder have ...
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
Gene therapy for some diseases, including Duchenne muscular dystrophy (DMD), can be tricky because the needed gene is often ...
StitchR, a new gene therapy technique, delivers large genes in two parts to treat muscular dystrophies by restoring critical proteins in animal models.
Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...
The FDA issued its first stamp of approval for a cell or gene therapy back in 2017 to Novartis' Kymriah. | The gene therapy ...
The approval marks the first time gene therapy will be available to treat patients with aromatic I-amino acid decarboxylase ...
PTC Therapeutics' Kebilidi gains FDA accelerated approval as the first brain-administered gene therapy in the U.S. for AADC ...
StitchR makes it possible to deliver larger payloads with current vectors, expanding the list of diseases targetable by gene therapies.